TransMedics Was Halved While the Business Kept Growing: The New CFO and Its Reiterated 2026 Target

TransMedics has been brutalized. Shares trade near $85, down roughly 30% this year and about 45% off the 52-week high near $156, with more than a quarter of the float sold short. On its face that reads like a broken medtech growth story. Then on September 10 the company did something odd for a business that broken: it hired a CFO from GE HealthCare's roughly $16 billion imaging unit and quietly restated that it still expects 2026 revenue of $737 million to $757 million, growth of about 22% to 25%.2026 revenue of $737 million to $757 million The headlines said one thing. The reiterated target says the operating story did not break.

Two different forces put the stock through the wringer this year, and keeping them apart matters because one concerns the business and the other concerns investors' willingness to trust it.

The first force is an activist-short campaign. In January 2025 Scorpion Capital published a report accusing TransMedics, the dominant maker of portable "warm perfusion" devices that keep donor organs alive in transit, of running what the short seller called a racketeering and organ-trafficking scheme, and it asked the FDA to suspend approval of the Organ Care System.FDA to suspend Pre-Market Approval The company called the claims inaccurate and misleading.inaccurate and misleading claims The episode stuck: short interest still stood at about 25% of the float in late August, with roughly 13 days to cover.25.11% of the public float

The second force is a genuine profit reversal inside the numbers. Revenue never broke. TransMedics grew 37% in 2025, to $605.5 million,$605.5 million, 37% increase and grew 21% in the June quarter, to $189.9 million,$189.9 million, 21% increase on rising use of the Organ Care System and its logistics service. What actually fell was earnings, not sales. Second-quarter operating margin nearly halved, to 12.5% from 23.2%, and adjusted earnings per share dropped to $0.44 from $0.92.$0.44 per diluted share vs $0.92 Part of 2025's reported $4.87 per share was a one-time tax benefit$4.87 per diluted share that flattered the year. Management says the margin hit is an investment phase — spending the flywheel into an OCS kidney program, a next-generation system, clinical trials, and a European logistics network built around newly acquired aircraft.

That is the central question for a holder or a watcher: is the profit collapse a hand-picked reinvestment that resets growth higher, or the first sign that a high-margin monopoly is getting ordinary? The cash-flow bridge points one way. Trailing free cash flow came in near $79 million — up more than threefold from the year before — against a cash balance of about $473 million and modest net debt. So the tape pain does not match the cash picture: the company is throwing off real money off a roughly $600 million revenue base even while it invests. This is not a stock that is cheap on that cash flow — a $2.9 billion market cap works out to roughly a low-single-digit yield — so the case is not "bought the dip on a bargain." The case is that the trajectory inflected before the market believed it.

The September move is management's loudest statement of that belief. Fernando Araujo, most recently CFO of GE HealthCare's Advanced Imaging Solutions segment, becomes CFO and treasurer on September 21; outgoing CFO Gerardo Hernandez shifts to a commercial advisory role for Latin America. And alongside that change TransMedics reiterated the $737 million to $757 million target, to be revisited with third-quarter results. None of this resolves the short thesis, and a new finance chief does not make the margins real. But placing a large-cap finance operator in the seat at the moment of maximum short pressure, and restating the growth number, is a continuity signal: management is telling skeptical investors the numbers it already disclosed still stand.

Here is what would prove this investment phase worked or failed over the next year. It works if revenue keeps compounding at or above roughly 20% through 2026 while operating margins stop falling and free cash flow climbs — then the spend was aimed at growth, margins rebuild from a low base, and the stock re-rates off a reset expectation. It fails if growth decelerates below that line while margins stay compressed, or if the short campaign acquires regulatory teeth, like the FDA acting on the petition to suspend OCS approvals. That second condition is the break: a regulatory move against the core device is a franchise event no valuation rescues.

I can be wrong again, and the near-term earnings hiccup is real, not imagined. But the market is still pricing the old risk profile — a quarter of the float short, expectations reset low — while the operating setup is already showing cash inflection and an intact growth target. This is not about excitement. It is about a business that may look a lot harder to dismiss once the next twelve months of free cash flow show up. AInvest's aggregate signal still labels the stock a Buy, and that matters less as a recommendation than as a sign that the crowd has not yet changed its mind.